Mon, Dec 29, 2014, 12:06 AM EST - U.S. Markets open in 9 hrs 24 mins


% | $
Quotes you view appear here for quick access.

Staples, Inc. Message Board

gswkool 112 posts  |  Last Activity: 22 hours ago Member since: Jan 2, 2012
  • Reply to

    Mark Fisher on Fast Money

    by foogie88 Dec 22, 2014 12:16 PM

    i don't trust a lot of these guys that go on tv spouting their opinions. how do you know what they say and what they do are not two different things? if he likes it so much, -let him buy it. for me way too early -SU is a good company in a bad oil market. until things play out more and price of oil stabilizes, no one knows where we are really at -my guess is as long as Saudis commit to keep pumping, price will remain low and price of oil companies will move lower as earnings adjustments are made to down side. watch all the 1Q earnings warnings in the sector -they're coming......

  • Reply to

    Near term outlook for pSivida

    by godwintom Dec 26, 2014 1:46 PM

    I've missed out on some good opportunities in the past because I liked the company but thought I could wait for a better price. I wish you good luck with that strategy. What would the price have to be for you to purchase shares? Anyhow, I think the price at this point is very reasonable. I'm not particularly worried about PSDV. I hate to see other investors miss the boat, esp. if they have held the shares for some time in the past. I've been down that road and when it happens it hurts......glta

  • Reply to

    Okay. Now it's time to cut some deals.

    by helpme_hanna Dec 26, 2014 11:00 AM
    gswkool gswkool Dec 27, 2014 1:15 PM Flag

    They need to prove their technology works before there will be any deal. RXI-109 is the only candidate in a position to garner attention. The other candidates are pre-clinical. You still need to wait for positive results for RXI-109. I haven't seen anything substantive enough to warrant a partnership......yet. So you may be disappointed in near term. I do look at a bunch of factors before investing. In this case it only warranted a small share purchase. Wtih small, speculative companies such as RXII, I adopt a "show me" attitude. I will reward progress with addiitonal purchases and dollar cost average over time. Fail me -give me bad news - and I will most likely sell some or all of my position. That strategy has worked out quite well for me. I do not get emotionally attached to my investments. You seem a little naive about how things work in biotech land and by the number of your posts you seem quite attached to this stock. One should always remain detached and diversify, esp. when investing in biotech land.........glta

  • Reply to

    Near term outlook for pSivida

    by godwintom Dec 26, 2014 1:46 PM
    gswkool gswkool Dec 27, 2014 12:44 PM Flag

    Agree on forgetting about buyout -too early in the game. As for 2015, -there can be other catalysts. Early 2015 they expect to complete PIII Uveitis enrollment. They also expect to meet with FDA to confirm strategy. Confirmation of one trial only for Uveitis is important. PSDV also working on additional collaborations. Possible additional clinical progress for vein occlusion and dry AMD indications. Vein occlusion is 200,000 patient market. Dry AMD is huge market. For Tethadur an IND may come late in the year if at all. There may still be news on partnership front though. Expect another busy year for PSDV. I'm not a day trader. IMHO long term this company has big potential. My return on share purshases has been close to 100% since I began purchases two years ago. How can I be diappointed with that? Investing requires good timing but also a lot of patience, esp. with biotechs.......GLTA

  • Reply to

    Another year no approval.

    by cmhe Dec 23, 2014 2:55 AM
    gswkool gswkool Dec 27, 2014 11:31 AM Flag

    the teva patent will expire ......looks like before the courts act on their will have had time to switch patients to the new formulation - however judging by recent action of ESRX PBM, when the genreic comes out will PBMs find enough of a benefit to allow patients to continue on TEVA's new formulation or will they push patients to go generic? It's possible the latter will happen. So Teva looks to be winning the game now, -but it's certainly not over. I'm holding onto my stock -I got it at a good price anyway. IMHO this stock will be trading at higher price by end of 2015....glta

  • Reply to

    Okay. Now it's time to cut some deals.

    by helpme_hanna Dec 26, 2014 11:00 AM
    gswkool gswkool Dec 27, 2014 11:24 AM Flag

    First they need some positive clinical results. What kind of deal are you thinking of? Unfortunately they are not far enough along, -which is why they most likey entered into the deal with Hapten. Having two phase II compunds is better than having one -they are hedging their bets. At what cost? I have small amount of stock here -i'm not going to over analyze - time will tell if they did right thing for shareholders. Companies can have early stage pipelines and larger market caps depending on their pedigree i.e. their standing in scientific community. The low valuation to me indicates either they are not getting recognition they deserve or they are seconds rate. Again, time will tell.....

  • imho we should get positive news flow in 2015 with more to report on as pipeline continues to build out. deal with NVS was NOT for existing pipeline according to press release. together NVS & BLRX will select new candidates. so pipeline will continue to grow. that is just w/NVS. NVS is smart too -by taking an equity stake they gain as BLRX increases in value. i'm hopeful as we go forward into the new year. as they continue to tell their story to investment community, hopefully they will get a little more recognition and interest from both investors and prospective partners. ...glta

  • Reply to

    SU will hit 20 soon

    by listen_jockers Oct 11, 2014 2:28 PM
    gswkool gswkool Dec 26, 2014 11:19 AM Flag

    the earnings estimates continue to fall. SU is a quality, well run company....but when it comes down to it, it is still just a commodity producer and profits are tied to price of oil. i'm in the camp that will not buy shares until oil stablilizes and we get a sense of what their earnings will be going forward. other signs to watch for is shakeout of small players and consolidation. when this happens I will buy shares in oil companies again. we're just in the early rounds of all this playing out imho................glta

  • Reply to


    by madetotroll Dec 24, 2014 7:17 AM
    gswkool gswkool Dec 24, 2014 2:14 PM Flag

    Honestly, if you have insubstantial amount of shares and no representation on the board -they won't be paying any attention to you. They will most likely not even read any communications coming from you after your first rant. You are wasting your efforts. So....given that you will be completely ineffectual - if you are that unhappy you are best off selling your shares and moving on.....if I were that unhappy with mgmt that is what i would do....imho.....

  • gswkool gswkool Dec 23, 2014 8:26 PM Flag

    it's hard to tell the snake oil salesmen from the real deal. I have shares in Osiris and they have FDA approved stem cell products and just signed distribution deal with Stryker. I bailed out of NBS with a loss. Do you have any other stem cell companies that you think have some real/quality science behind them?

  • Reply to

    Merry Christmas from Paul Ashton

    by murphyjan_2000 Dec 23, 2014 1:37 PM
    gswkool gswkool Dec 23, 2014 6:25 PM Flag

    another bio-dump ......geez, my bowels hurt ...............i'm sure his does also.....we're all on the receiving end of this's to a better New Year .........please.............

  • gswkool gswkool Dec 23, 2014 6:21 PM Flag

    market seems to be ignoring any good news for this small biotech. I expect more of same. it may go up a little tomorrow -.............then watch it go back down. price appreciation will happen eventually though with continued good news and build-out of their pipeline and for those that believe there is a good story developing here, use low share price as a time to accumulate.....GLTA

  • gswkool gswkool Dec 23, 2014 2:39 PM Flag

    my guess is people dumping funds that specialize in pharma/biotech on the ESRX news - unfortunately it is indiscriminate selling - that's why i avoid funds and buy individual stocks - you're right -the investment thesis for PSDV is still intact and "should" have been immune to such news. For me, the biotech dump is an opportunity to pick up shares cheaply. should be interesting to see what the response is to ESRX - pharma and biotech has a lot to lose -and they have powerful lobby -

  • Reply to

    Blame It on Express Scripts

    by korthh Dec 23, 2014 1:40 PM
    gswkool gswkool Dec 23, 2014 2:30 PM Flag

    the pharmas and biotechs should get together and decide not to sell any medicines to ESRX. See if they remain the biggest PBM then.....

  • gswkool gswkool Dec 22, 2014 4:06 PM Flag

    i would have thought the market would respond more positively - anyway, it's an opportunity to accumulate more shares if you think BLRX has something of value. I already did just gotta wait and see....patience is a must when it comes to biotech vesting.....and diversifying your bets.........glta

  • gswkool gswkool Dec 21, 2014 12:08 PM Flag

    so what -he didn't make his fortune in biotech and the article states his record is spotty when it comes to biotech -i would not buy shares in Aegerion personally......

  • gswkool gswkool Dec 21, 2014 11:56 AM Flag

    To me both companies are winners. I've owned shares in both for some time and I'm very happy with the investments. I will say that ISIS has come on strongly as of late and if I were to purchase more shares in one of the companies, it would be ISIS. Long term, both companies will bear fruit IMHO.....GLTA

  • Reply to

    Hapten Sciences??

    by golongin2008 Dec 19, 2014 2:32 PM
    gswkool gswkool Dec 19, 2014 8:29 PM Flag

    Wasn't it originally named "Hapless Pharmaceuticals" but changed its name in the hopes some sucker would come calling with their checkbook? I can't remember - i'm a little dizzy from RXII falling stock price...

  • gswkool by gswkool Dec 19, 2014 4:33 PM Flag

    Adocia scored a nice deal on their ultra rapid insulin formulation technology:

    "The total up-front and milestone payments could reach up to $570 million; Adocia will receive a total upfront fee of $50 million with the potential for future payments of up to $280 million if the product reaches certain development and regulatory milestones, and sales milestones up to $240 million, as well as tiered sales royalties. Lilly shall also reimburse Adocia for certain research and development expenses during the terms of the agreement."

    The deal was not with Biodel. Makes me wonder if there is any future here. You win some and you lose some. The question is how long to stick around before throwing in the towel and taking a writeoff.....GLTA

  • gswkool by gswkool Dec 19, 2014 1:57 PM Flag

    cash and common stock -how much of the common stock did they give to Hapton? Actually, what's the difference -who even knows if RXII common stock is worth anything. And maybe Hapton's drug candidate is worth something or not. The deal gives RXII a later stage drug, - shouldn't they really be putting their money into their own drug candidates? at this point, ...............whatever.........I will eventually take the loss as a write-off if I have to. ..................glta

17.98+0.16(+0.90%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.